Evidence map›Paper›PMID 31095406›Full record

ReviewAssay and drug development technologies

The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons.

Elizabeth R Sharlow, Mehmet Murat Koseoglu, George S Bloom, John S Lazo

Abstract readReview
In one paragraph

Review in Assay and drug development technologies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elizabeth R SharlowDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia.
Mehmet Murat KoseogluDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia.
George S BloomDepartment of Biology, University of Virginia, Charlottesville, Virginia.
John S LazoDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia.

Funding

A Precision high content screening assay for AB-mediated neuronal cell cycle reentryR01AG063400 · NIA · UNIVERSITY OF VIRGINIA · PI SHARLOW, ELIZABETH · 2019 to 2021
$1.4M
NIA NIH HHS R01 AG063400
6 · The paper itself

Abstract

Neurological diseases comprise more than a thousand ailments that adversely affect the brain and nervous system. When grouped together, these neurological conditions impact an estimated 100 million individuals in the United States and up to a billion people worldwide, making drug discovery efforts imperative. However, recent research and development efforts for these neurological diseases, including Alzheimer's disease and amyotrophic lateral sclerosis, have been exceedingly disappointing and typify the challenges associated with translating

Indexed as

Drug DiscoveryDrug Evaluation, PreclinicalHumansInduced Pluripotent Stem CellsNervous System DiseasesNeuronsNeuroprotective AgentsNeuroprotective AgentsinducibleneuronNPCpluripotent

Identifiers

PMID31095406
PMCPMC7047103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.